Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with SHR-8068 and Chemo in Mutated NSCLC
NCT06335355Phase 3Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Oct 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab, CS1002 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
adebrelimabCS1002
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06335355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335355.